Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03299309
Other study ID # Pro00079843
Secondary ID
Status Active, not recruiting
Phase Phase 1
First received
Last updated
Start date June 29, 2018
Est. completion date April 2025

Study information

Verified date May 2024
Source Duke University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary goal of this prospective clinical trial is to evaluate the safety of PEP-CMV in patients with recurrent medulloblastoma and malignant glioma. Patients with histologically-proven medulloblastoma or malignant glioma who had received prior therapy for their initial diagnosis and subsequently had tumor recurrence/progression may be enrolled any time after recurrence/progression regardless of prior adjuvant therapy. PEP-CMV is a vaccine comprised of Component A, a synthetic long peptide (SLP) of 26 amino acid residues from human pp65. In May 2021, enrollment on the study was temporarily suspended due to delays in vialing the PEP-CMV study vaccine.


Description:

Once a patient has enrolled onto this study, prior therapy will be terminated and patients will receive temozolomide 200 mg/m2/day x 5 days. If they are receiving bevacizumab at the time of enrollment, they will continue bevacizumab 10 mg/Kg every 14 days. Patients who are ≥ 18 years of age will receive a tetanus (Td) booster at the time of enrollment. Immunotherapy begins with a Tetanus (Td) pre-conditioning vaccine delivered intradermally (i.d.) in the right groin at the site of the vaccine injection 6-24 hours prior to the first vaccine on day 21. The PEP-CMV vaccine will be administered as follows: PEP-CMV Component A mixed with Montanide ISA-51 (1:1 volume ratio) intradermally administered half in the RIGHT groin and half in the LEFT groin. The first 3 PEP-CMV vaccines will occur every 2 weeks, then PEP-CMV vaccines will continue monthly (+/- 2 weeks) for no more than 10 years. Blood will be obtained for immune system monitoring. In May 2021, enrollment on the study was temporarily suspended due to delays in vialing the PEP-CMV study vaccine.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 30
Est. completion date April 2025
Est. primary completion date April 27, 2023
Accepts healthy volunteers No
Gender All
Age group 3 Years to 35 Years
Eligibility Inclusion Criteria: 1. Patients who are 3 - 35 years old 2. Histopathologically proven previous diagnosis of medulloblastoma or Grade III or IV glioma. 3. Radiology evidence of recurrent medulloblastoma (reMB) or recurrent Grade III and IV glioma. Patients will be considered for a biopsy or resection of the recurrent/progressive tumor at the discretion of the treating neurosurgeon and neuro-oncologist. 4. Brain MRI within one month prior to enrollment. 5. Received prior therapy for their initial diagnosis prior to recurrence/progression or who are unable to receive radiation therapy due to genetic disorders that put them at significant risk for radiation-induced secondary malignancies (i.e. Gorlin's syndrome or NF1 mutation). 6. Patients with neurological deficits should have deficits that are stable for a minimum of 2 weeks prior to registration. 7. Karnofsky Performance Status (KPS) of = 60% (KPS for > 10 years of age) or Lansky performance Score (LPS) of = 60 (LPS for = 10 years of age) assessed within 2 weeks prior to registration. Patients who are unable to walk because of paralysis but who are up in a wheel chair will be considered ambulatory for the purposes of the performance score. 8. Bone Marrow: - ANC (Absolute neutrophil count) = 1000/µl (unsupported)*. - Platelets = 100,000/µl (unsupported)*. - Hemoglobin > 8 g/dL (may be supported). 9. Renal: • Serum creatinine = upper limit of institutional normal. 10. Hepatic: - Bilirubin = 1.5 times upper limit of normal for age. - SGPT (ALT) = 3 times institutional upper limit of normal for age. - SGOT (AST) = 3 times institutional upper limit of normal for age. 11. Patients of childbearing or child-fathering potential must be willing to use a medically acceptable form of birth control, which includes abstinence, while being treated on this study. 12. Signed informed consent according to institutional guidelines must be obtained prior to registration. 13. Any prior chemoradiotherapy is allowed. Exclusion Criteria: 1. Pregnant or need to breast feed during the study period (Negative serum pregnancy test required). 2. Active infection requiring treatment or an unexplained febrile (> 101.5 degrees F) illness. 3. Known immunosuppressive disease or human immunodeficiency virus infection. 4. Patients with active renal, cardiac (congestive cardiac failure, myocardial infarction, myocarditis), or pulmonary disease. 5. Patients receiving concomitant immunosuppressive agents for medical condition. 6. Patients who need definitive radiotherapy for treatment of recurrent MB or recurrent Grade III or IV glioma. 7. Patients receiving any other investigational drug therapy. 8. Patients on corticosteroids > 0.1 mg/Kg/day (i.e. > the maximum dose of 4 mg/day). 9. Patients with any clinically significant unrelated systemic illness (serious infections or significant cardiac, pulmonary, hepatic or other organ dysfunction). 10. Patients with inability to return for follow-up visits or obtain follow-up studies required to assess toxicity to therapy.

Study Design


Intervention

Drug:
PEP-CMV
Patients receive temozolomide (TMZ) 200 mg/m2/day x 5 days. On day 20, patients will receive a Tetanus-diphtheria pre-conditioning vaccination with Td (tetanus, diphtheria toxoid, adsorbed). Immunotherapy begins the following day, on day 21, with injection of the PEP-CMV vaccine as follows: PEP-CMV Component A mixed with Montanide ISA-51 intradermally administered half in the RIGHT groin and half in the LEFT groin.

Locations

Country Name City State
United States Duke University Medical Center Durham North Carolina

Sponsors (3)

Lead Sponsor Collaborator
Daniel Landi Annias Immunotherapeutics, Inc., Pediatric Brain Tumor Foundation

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of patients with unacceptable toxicity Evaluate the safety of PEP-CMV in pediatric patients with recurrent MB or recurrent Grade III/IV glioma 2 weeks after the 3rd PEP-CMV vaccine on the last enrolled patient
Secondary Mean or median change from baseline at each follow-up assessment in ELISPOT (IFN-?) Quantitate the immune response to the components of the PEP-CMV vaccine by ELISPOT 24 months
Secondary Mean or median change from baseline at each follow-up assessment in ELISA (gB-KLH) Quantitate the immune response to the components of the PEP-CMV vaccine by ELISA 24 months
See also
  Status Clinical Trial Phase
Terminated NCT02764151 - First in Patient Study for PF-06840003 in Malignant Gliomas Phase 1
Completed NCT02526017 - Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers Phase 1
Completed NCT00953121 - Bevacizumab Plus Irinotecan Plus Carboplatin for Recurrent Malignant Glioma (MG) Phase 2
Completed NCT00766467 - A Randomized Placebo-Controlled Trial of Armodafinil (Nuvigil) for Fatigue in Patients With Malignant Gliomas Phase 2
Active, not recruiting NCT03233204 - Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) Phase 2
Recruiting NCT05045027 - Simultaneous Multinuclear Metabolic MRI in Newly Diagnosed or Recurrent Glioma Early Phase 1
Completed NCT02507583 - Antisense102: Pilot Immunotherapy for Newly Diagnosed Malignant Glioma Phase 1
Completed NCT04109209 - Psychological Intervention For Brain Tumor Caregivers N/A
Recruiting NCT04937413 - The PCSK9i Inhibitor Evolocumab - a Surgical Trial of Pharamcodynamics and Kinetics Evaluation Early Phase 1
Completed NCT03615404 - Cytomegalovirus (CMV) RNA-Pulsed Dendritic Cells for Pediatric Patients and Young Adults With WHO Grade IV Glioma, Recurrent Malignant Glioma, or Recurrent Medulloblastoma Phase 1
Active, not recruiting NCT04175301 - Effect H2 Water on QoL of Patients Receiving Radiotherapy for High Grade Gliomas. Phase 2
Terminated NCT02659800 - Study of the Effect NT-I7 on CD4 Counts in Patients With High Grade Gliomas Phase 1
Active, not recruiting NCT02323880 - Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas Phase 1
Completed NCT00782756 - Bevacizumab, Temozolomide and Hypofractionated Radiotherapy for Patients With Newly Diagnosed Malignant Glioma Phase 2
Terminated NCT02855086 - Cetuximab-IRDye 800CW in Detecting Tumors in Patients With Malignant Glioma Undergoing Surgery Phase 1/Phase 2
Completed NCT02861222 - Myocet® in Children With Relapsed or Refractory Non-brainstem Malignant Glioma Phase 1
Completed NCT00634231 - A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors Phase 1
Completed NCT01792505 - Dendritic Cell Vaccine With Imiquimod for Patients With Malignant Glioma Phase 1
Completed NCT00190723 - A Study of LY317615 in Patients With Brain Tumors Phase 2
Recruiting NCT04323046 - Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults Phase 1